Invivyd, Inc. Form 8-K Summary
Business Context and Reporting Period
Invivyd, Inc. (IVVD), a Delaware corporation, filed this Current Report on Form 8-K on April 18, 2025. The filing discloses the entry into a material definitive agreement to secure financing for working capital and general business purposes.
Key Financial Metrics and Debt Structure
The Company entered into a Loan and Security Agreement with Silicon Valley Bank, a Division of First-Citizens Bank & Trust Company, establishing a senior secured term loan facility with an aggregate principal amount of up to $30 million. The facility is structured as follows:
- Term A Loans: Up to $10 million available from August 15, 2025, through December 31, 2026, subject to financial covenants.
- Term B Loans: Up to $10 million available upon achievement of certain net product revenue milestones, ending June 30, 2027.
- Term C Loans: Up to $10 million available upon achievement of certain net product revenue milestones, ending June 30, 2027.
Interest and Fees:
- Interest Rate: The greater of (WSJ Prime Rate minus 0.25%, capped at 9.00%) or 6.00% per annum.
- Final Payment Fee: 4.50% of the aggregate principal amount advanced, payable at maturity or prepayment.
- Commitment Fee: 1.00% of the Term Facility, payable by July 1, 2027, unless loans are funded prior to that date.
- Prepayment Premiums: 3.0% (within 1 year), 2.0% (years 1-2), 1.0% (years 2-3), and 0.0% (after 3 years).
Repayment Terms: Loans mature on March 1, 2029. Principal repayment begins April 1, 2027, in 24 equal monthly installments (or 12 installments if the interest-only period is extended to April 1, 2028 upon meeting revenue milestones).
Collateral: The obligations are secured by a pledge of substantially all Company assets, excluding intellectual property.
Material Changes and Covenants
This filing represents a material change in the Company's capital structure through the creation of a new debt obligation. The agreement imposes significant affirmative and negative covenants, including limitations on incurring additional debt, granting liens, making acquisitions, paying dividends, and changing the line of business.
Financial Covenants:
- Minimum Net Product Revenue: Required commencing the quarter following the advance of any loans.
- Liquidity/EBITDA Requirement: Commencing with the quarter ending December 31, 2025 (or earlier if loans exceed $15 million), the Company must maintain either a certain minimum EBITDA or a "Minimum Cash Threshold." The Minimum Cash Threshold is defined as the greater of: (i) six-month Cash Burn plus outstanding loans, or (ii) two times the outstanding loans.
- U.S. Sales Condition: If the Company ceases active sales of a product in the U.S., it must maintain the Minimum Cash Threshold at all times.
Outlook, Risks, and Contingencies
The proceeds are intended for working capital and general business purposes. The filing highlights that the ability to draw Term B and Term C loans is contingent upon achieving specific net product revenue milestones. Failure to meet financial covenants or maintain the Minimum Cash Threshold could result in an Event of Default, allowing the Lender to accelerate all outstanding amounts.
The Company is classified as an emerging growth company. The filing includes standard representations and warranties, which are noted as risk allocation mechanisms rather than statements of fact regarding the Company's current condition.
Key Facts for Investor Verification
- Verify the Company's current cash position against the "Minimum Cash Threshold" requirements defined in the loan agreement.
- Monitor progress toward the net product revenue milestones required to access the $20 million in Term B and Term C loans.
- Review the Company's ability to meet the quarterly minimum net product revenue covenant starting after the first loan advance.
- Assess the impact of the 4.50% final payment fee and potential prepayment premiums on future liquidity planning.
- Confirm whether any subsidiaries will be required to become co-borrowers or guarantors as the Company expands.